Meeting
2024 ASCO Genitourinary Cancers Symposium
Performance of the OncoUrine test on predicting patients who can avoid Re-TURBT and prognosis: A prospective, multicenter clinical study.
Authors
Xiao Yang
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Xiao Yang , Lingkai Cai , Bing Zhen , Lin Yuan , Zhenqian Qin , Xinfeng Chen , Jie Han , Xuping Jiang , Yaqun Xin , Hongling Yuan , Dandan Cao , Qiang Lu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05112523
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 623)
DOI
10.1200/JCO.2024.42.4_suppl.623
Abstract #
623
Poster Bd #
H8
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Somatic genomic alterations in urothelial cancer: Results of the Cancer Genome Atlas (TCGA) bladder cancer (BC) analysis.
First Author: Jonathan E. Rosenberg
Poster
2017 Genitourinary Cancers Symposium
Next generation sequencing of non-muscle invasive bladder cancer to reveal potential biomarkers and rational therapeutic targets.
First Author: Eugene J. Pietzak III
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.
First Author: Petros Grivas
Poster
2020 Genitourinary Cancers Symposium
Comprehensive targeted gene profiling to determine the genomic signature likely to drive progression of high-grade nonmuscle invasive bladder cancer to muscle invasive bladder cancer.
First Author: Abedalrhman Alkhateeb